PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1994; 87(Suppl 21): 20–24.
PMCID: PMC1294261

Oral bile acids in cystic fibrosis-associated liver disease.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (940K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Roy CC, Weber AM, Morin CL, Lepage G, Brisson G, Yousef I, Lasalle R. Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. J Pediatr Gastroenterol Nutr. 1982;1(4):469–478. [PubMed]
  • Williams SG, Hayller KM, Hodson ME, Westaby D. Prognosis in cystic fibrosis. N Engl J Med. 1992 Oct 22;327(17):1244–1245. [PubMed]
  • de Caestecker JS, Jazrawi RP, Petroni ML, Northfield TC. Ursodeoxycholic acid in chronic liver disease. Gut. 1991 Sep;32(9):1061–1065. [PMC free article] [PubMed]
  • Colombo C, Setchell KD, Podda M, Crosignani A, Roda A, Curcio L, Ronchi M, Giunta A. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr. 1990 Sep;117(3):482–489. [PubMed]
  • Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut. 1990 Aug;31(8):918–921. [PMC free article] [PubMed]
  • Galabert C, Montet JC, Lengrand D, Lecuire A, Sotta C, Figarella C, Chazalette JP. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr. 1992 Jul;121(1):138–141. [PubMed]
  • Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology. 1992 Apr;15(4):677–684. [PubMed]
  • Colombo C, Crosignani A, Assaisso M, Battezzati PM, Podda M, Giunta A, Zimmer-Nechemias L, Setchell KD. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology. 1992 Oct;16(4):924–930. [PubMed]
  • Maurage C, Lenaerts C, Weber A, Brochu P, Yousef I, Roy CC. Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: an autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1989 Jul;9(1):17–20. [PubMed]
  • Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child. 1991 Jun;66(6):698–701. [PMC free article] [PubMed]
  • FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993 Jan;122(1):1–9. [PubMed]
  • Tizzano EF, Buchwald M. Cystic fibrosis: beyond the gene to therapy. J Pediatr. 1992 Mar;120(3):337–349. [PubMed]
  • Fitz JG, Basavappa S, McGill J, Melhus O, Cohn JA. Regulation of membrane chloride currents in rat bile duct epithelial cells. J Clin Invest. 1993 Jan;91(1):319–328. [PMC free article] [PubMed]
  • Hofmann AF, Popper H. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet. 1987 Aug 15;2(8555):398–399. [PubMed]
  • Graham N, Manhire AR, Stead RJ, Lees WR, Hodson ME, Batten JC. Cystic fibrosis: ultrasonographic findings in the pancreas and hepatobiliary system correlated with clinical data and pathology. Clin Radiol. 1985 Mar;36(2):199–203. [PubMed]
  • Gaskin KJ, Waters DL, Howman-Giles R, de Silva M, Earl JW, Martin HC, Kan AE, Brown JM, Dorney SF. Liver disease and common-bile-duct stenosis in cystic fibrosis. N Engl J Med. 1988 Feb 11;318(6):340–346. [PubMed]
  • Nagel RA, Westaby D, Javaid A, Kavani J, Meire HB, Lombard MG, Wise A, Williams R, Hodson ME. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet. 1989 Dec 16;2(8677):1422–1425. [PubMed]
  • Thompson GN. Excessive fecal taurine loss predisposes to taurine deficiency in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1988 Mar-Apr;7(2):214–219. [PubMed]
  • Smith LJ, Lacaille F, Lepage G, Ronco N, Lamarre A, Roy CC. Taurine decreases fecal fatty acid and sterol excretion in cystic fibrosis. A randomized double-blind trial. Am J Dis Child. 1991 Dec;145(12):1401–1404. [PubMed]
  • Darling PB, Lepage G, Leroy C, Masson P, Roy CC. Effect of taurine supplements on fat absorption in cystic fibrosis. Pediatr Res. 1985 Jun;19(6):578–582. [PubMed]
  • Haug K, Schrumpf E, Barstad S, Fluge G, Halvorsen JF. Epidemiology of ulcerative colitis in western Norway. Scand J Gastroenterol. 1988 Jun;23(5):517–522. [PubMed]
  • Perdigoto R, Wiesner RH. Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. Gastroenterology. 1992 Apr;102(4 Pt 1):1389–1391. [PubMed]
  • Vogel W, Kathrein H, Judmaier G, Braunsteiner H. Deterioration of primary biliary cirrhosis during treatment with ursodeoxycholic acid. Lancet. 1988 May 21;1(8595):1163–1163. [PubMed]
  • Nittono H, Tokita A, Hayashi M, Nakatsu N, Obinata K, Watanabe T, Yamashiro Y, Yabuta K, Miyano T. Ursodeoxycholic acid in biliary atresia. Lancet. 1988 Mar 5;1(8584):528–528. [PubMed]
  • Nakagawa M, Colombo C, Setchell KD. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology. 1990 Aug;12(2):322–334. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press